ProQR Therapeutics PRQR 深 滬

美股夜盘 | Republic Power涨38.76%，巨龙在线涨22.55%

Tvardi Therapeutics Inc.涨-10.80%；Dreamland涨-9.80%；有信科技涨-9.33%

07-09 08:05

美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级

今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元

06-30 10:14

美股大行评级 | 潜在涨幅90.66%！Tango Therapeutics获杰富瑞升目标价至60美元，上调至"买入"评级

今日重点评级关注：杰富瑞：上调Tango Therapeutics评级至"买入"，目标价从27美元升至60美元；Susquehanna：维持安森美半导体"积极"评级，目标价从120美元升至140美元

06-29 15:49

小型生物科技公司ProQR Therapeutics凭借早期试验成功获得礼来投资

普罗科治疗股份有限公司（ProQR Therapeutics N.V.，纳斯达克代码：PRQR）公布在研RNA编辑疗法AX-0810的积极1期临床早期数据，同时...

06-25 22:07

ProQR Therapeutics Prices Registered Direct Offering Of 27,624,310 Shares At $1.81 Per Share For Total Gross Proceeds Of ~$50M; Also Enters Private Placement With Lilly For ~5.1M Shares At Same Offer Price

ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,...

06-25 18:39

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

ProQR Therapeutics announced positive Phase 1 data for AX-0810, showing dose-dependent NTCP modulation with up to 8-fold increase in bile acids, meeting predefined targets. AX-0810 demonstrated favorable safety and pharmacokinetics, with an eight-week half-life. These findings support the advancement of AX-0811, a next-generation candidate, and future studies in biliary atresia. The company plans to present full Phase 1 data later this year and i...

06-25 10:25

ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.10) per share from the same period last year.

05-12 19:13

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

ProQR Therapeutics N.V. announced its Annual General Meeting (AGM) will take place on June 2, 2026, in Amsterdam. Shareholders can access relevant documents on ProQR’s website or the SEC’s site. The company highlights its Axiomer™ RNA editing technology, which uses ADAR to correct RNA mutations, potentially treating diverse diseases. ProQR focuses on developing transformative RNA therapies for both rare and prevalent conditions.

05-04 12:00

ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI

04-08 20:02

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

04-08 12:00